WebNov 6, 2024 · 在13例基线有脑转移的患者中,orr为61.5%,dcr为100%。 3例患者基线有颅内可测量病灶,1例颅内肿瘤达到PR,2例为SD。 此外,伊鲁阿克在克唑替尼耐药的ROS1阳性NSCLC患者中显示出疗效信号,9例克唑替尼耐药的患者中,ORR为22.2%(2例PR),DCR为66.7%,6个月的缓解率为100%,截至数据分析,患者仍在 ... WebIn the provided production report template, you’ll have a place to record the day's call times.. Crew Call:The time the crew arrives to set.You’ll find this on the call sheet.; Shoot Call:The …
Randomized, phase II trial of sequential hepatic arterial infusion ...
Web>All secondary efficacy endpoints (PFS, TTP, ORR, CBR, DoR) significantly improved with the addition of trastuzumab (data not shown). >Addition of trastuzumab to chemotherapy was well tolerated, with no difference in the overall safety profile between treatment arms, including cardiac AEs. >Trastuzumab in combination with chemotherapy is a new WebAug 16, 2024 · PFS, ORR, DOR, DCR, TTP: 14.6 versus 13.0 months: 150: HR 0.79 (95% CI 0.63–0.99); p = 0.0180: Note: All clinical trials were superiority trials except the REFLECT trial that was a non-inferiority trial. c \u0026 w insulations
Efficacy Results from the ToGA Trial: A Phase III Study of …
Websubstantiated durable ORR has been used to support traditional approval in select malignancies, but magnitude of effect, relief of tumor-related symptoms, and drug toxicity … Web(1) Background: Cabozantinib is approved in sorafenib-exposed advanced hepatocellular carcinoma (aHCC). We evaluated the real-life pattern of use, efficacy, and tolerability of cabozantinib in aHCC. (2) Methods: This territory-wide study included consecutive aHCC patients who received cabozantinib between February 2024 and September 2024 in Hong … WebOct 21, 2024 · We retrospectively analyzed data of all our pts with locally advanced (LA) or metastatic (M) BTC who received FOLFIRINOX as a first-line therapy from 12/2013 to 11/2024 at Paul Brousse university hospital. The main endpoints were OS, TTP, ORR, DC, secondary resection and toxicity. Results east and west longitude